pentobarbital will reduce the extent or result of terbinafine by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep an eye on.

fentanyl iontophoretic transdermal program and pentobarbital equally enhance sedation. Prevent or Use Alternate Drug. Restrict use to clients for whom alternative therapy alternatives are insufficient

pentobarbital will reduce the extent or impact of pantoprazole by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Importance Unknown.

pentobarbital will decrease the level or result of phenytoin by affecting hepatic enzyme CYP2C9/ten metabolism. Use Caution/Watch.

pentobarbital will lessen the extent or result of etravirine by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Watch.

pentobarbital will lower the extent or effect of doxorubicin liposomal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Watch.

pentobarbital and olopatadine intranasal both raise sedation. Stay away from or Use Alternate Drug. Coadministration increases chance of CNS depression, which may result in additive impairment of psychomotor performance and lead to daytime impairment.

If not able to avoid, double recent pralsetinib dose starting on Day seven of coadministration with powerful CYP3A inducer. Immediately after inducer continues to be discontinued for a minimum of 14 days, resume previous pralsetinib dose.

pentobarbital will lessen the extent or impact of propafenone by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Small/Importance Unidentified.

pentobarbital will decrease the extent or influence of bosentan by impacting hepatic enzyme CYP2C9/10 metabolism. Small/Significance Unknown.

pentobarbital will decrease the extent or outcome of fosphenytoin by impacting hepatic enzyme CYP2C9/ten metabolism. Use Warning/Check.

pentobarbital check here will lower the extent or impact of budesonide by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep an eye on.

The use of barbiturates as sedatives from the postoperative surgical time period and as adjuncts to cancer chemotherapy is effectively set up

Monoamine oxidase inhibitors (MAOI) might inhibit barbiturate metabolism and lengthen barbiturate outcomes; check carefully